 Placebo treatment Ecuadorian cutaneous leishmaniasis Pentavalent antimony standard treatment leishmaniasis administrable agent allopurinol ribonucleoside subject several clinical trials study agents patients Ecuadorian cutaneous leishmaniasis Patients treatment groups mean reduction lesion size patients Pentostam mg Sb/kg/day days weeks wide range individual values lesions first week therapy lesion re-epithelialized post-treatment followup Pentostam patients degree lesion resolution initial healing rate patient evidence relapse month complete healing rate month observation period Patients untreated control group high rate patients re-epithelialized lesions months observation initial healing rate mean reduction lesion size untreated patients weeks patients allopurinol ribonucleoside QID probenecid QID days Lesions patients time month followup rate